SCHEMBL4220093

SCHEMBL4220093

O=C(O)c1ccc(-c2cccc(Cl)c2)cc1Nc1ccc2c(c1)OCO2

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIK1 P39086 2/20 0.59
MAPT P10636 7/20 0.54
RAB9A P51151 6/20 0.54
NPC1 O15118 5/20 0.54
SMN1; SMN2 Q16637 4/20 0.54
KMT2A Q03164 3/20 0.54
MEN1 O00255 1/20 0.54
LMNA P02545 1/20 0.54
MAPK1 P28482 1/20 0.54
FABP3 P05413 1/20 0.53
FABP4 P15090 1/20 0.53
FABP5 Q01469 1/20 0.53
GAA P10253 1/20 0.53
TP53 P04637 1/20 0.52
HPGD P15428 1/20 0.52
CNR1 P21554 1/20 0.52
AKR1C3 P42330 1/20 0.51
AKR1C2 P52895 1/20 0.51
DCLRE1B Q9H816 1/20 0.47
ACLY P53396 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4227799 0.90 GRIK1 (0.53) GRIK1MAPTRAB9ANPC1SMN1; SMN2
SCHEMBL4212903 0.88 MEN1 (0.51) GRIK1MAPTRAB9ANPC1SMN1; SMN2
SCHEMBL4223945 0.85 MAPT (0.47) GRIK1MAPTRAB9ANPC1SMN1; SMN2
SCHEMBL2274216 0.83 RAB9A (0.60) GRIK1MAPTRAB9ANPC1SMN1; SMN2
SCHEMBL4219139 0.82 NPC1 (0.50) GRIK1MAPTRAB9ANPC1SMN1; SMN2
SCHEMBL4211160 0.81 ACLY (0.60) GRIK1MAPTRAB9ANPC1FABP4
SCHEMBL4225722 0.80 AKR1C3 (0.64) GRIK1RAB9ANPC1SMN1; SMN2KMT2A
SCHEMBL4218151 0.79 KMT2A (0.52) GRIK1MAPTRAB9ANPC1SMN1; SMN2
SCHEMBL4227637 0.79 RAB9A (0.56) GRIK1MAPTRAB9ANPC1SMN1; SMN2
SCHEMBL4215681 0.79 GRIK1 (0.54) GRIK1KMT2AMEN1CNR1AKR1C3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8327467-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2012-12-11 US disclosed
US-8327467-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2012-12-11 US disclosed
US-8327467-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2012-12-11 US disclosed
EP-1860098-B1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO LTD (JP) 2012-11-14 EP disclosed
US-20090105474-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-04-23 US disclosed
US-20090105474-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-04-23 US disclosed
US-20090105474-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-04-23 US disclosed
EP-1860098-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-11-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105474-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF MMP13, MMP11, MMP3 GRIK1 469/4885MAPT 4791/4885RAB9A 2262/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.